Validation of the predictive value of circulating biomarkers in oncological patients under immunotherapy

Validation of the predictive value of circulating biomarkers in oncological patients under immunotherapy - BIOTRUST-ONC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037366

Enrollment

400

Registered

2025-07-09

Start date

2024-07-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oncological patients

Interventions

Group 1: Questionnaire/Examination Form, Blood Sampling

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients/subjects > 18 years - Treatment as part of palliative or adjuvant systemic therapy/immunotherapy - Cancer patients who are treated outpatient or inpatient setting at the Department of Hematology, Oncology and Palliative Medicine at the UMR - healthy, age- and gender-matched female subjects as a control group

Exclusion criteria

Exclusion criteria: - incapable of giving consent - Failure to meet an inclusion criterion

Design outcomes

Primary

Measure	Time frame
Investigation of temporal changes in the composition and concentration of extracellular vesicles (EVs) in peripheral blood during immunotherapy and their association with clinical response.	—

Secondary

Measure	Time frame
not specified	—

Countries

Germany

Contacts

Public ContactClaudia Maletzki

Universitätsmedizin Rostock - Department für Innere Medizin - Klinik und Poliklinik für Hämatologie, Hämostaseologie, Onkologie, Stammzelltherapie und Palliativmedizin

claudia.maletzki@med.uni-rostock.de+49 381 494 5745

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026